Q-Line Biotech (NSE:QLINE) Ending Cash Position: ₹126 Mil (As of Mar. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:QLINE Q-Line Biotech Ltd NSE:QLINE
14 GF Score
Price ₹531.80
! 2 Warning Signs
View Full Analysis

What is Q-Line Biotech Ending Cash Position?

Q-Line Biotech NSE:QLINE -1.12% 14 Ending Cash Position is ₹126 Mil as of Mar. 2025. GuruFocus rates NSE:QLINE with a GF Score™ of 14/100. The stock has 2 warning signs investors should review.

Q-Line Biotech's Ending Cash Position for the quarter that ended in Mar. 2025 was ₹126 Mil.

Q-Line Biotech's quarterly Ending Cash Position declined from Mar. 2023 (₹716 Mil) to Mar. 2024 (₹197 Mil) and declined from Mar. 2024 (₹197 Mil) to Mar. 2025 (₹126 Mil).

Q-Line Biotech's annual Ending Cash Position declined from Mar. 2023 (₹716 Mil) to Mar. 2024 (₹197 Mil) and declined from Mar. 2024 (₹197 Mil) to Mar. 2025 (₹126 Mil).

Q-Line Biotech Ending Cash Position Related Terms

Q-Line Biotech Ending Cash Position Historical Data

* Premium members only.

The historical data trend for Q-Line Biotech's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Q-Line Biotech Ending Cash Position Chart

Q-Line Biotech Annual Data
Trend Mar23 Mar24 Mar25
Ending Cash Position
715.95 197.14 126.40

Q-Line Biotech Semi-Annual Data
Mar23 Mar24 Mar25
Ending Cash Position 715.95 197.14 126.40
NSE:QLINE
14GF Score
Q-Line Biotech Ltd NSE:QLINE
Ending Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Q-Line Biotech Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Q-Line Biotech's Ending Cash Position for the fiscal year that ended in Mar. 2025 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=197.142+-70.747
=126

Q-Line Biotech's Ending Cash Position for the quarter that ended in Mar. 2025 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=197.142+-70.747
=126

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of ₹126 Mil mean?
Q-Line Biotech (NSE:QLINE) has a Ending Cash Position of ₹126 Mil as of Mar. 2025. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Q-Line Biotech and its competitors.
Is Q-Line Biotech's Ending Cash Position too high?
Q-Line Biotech's current Ending Cash Position is ₹126 Mil. Overall, Q-Line Biotech has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Q-Line Biotech's Ending Cash Position compare to ABT and SYK?
Q-Line Biotech's Ending Cash Position of ₹126 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Medical Devices & Instruments company?
A good Ending Cash Position depends on the Medical Devices & Instruments industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Q-Line Biotech and its competitors. Q-Line Biotech's current Ending Cash Position is ₹126 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Q-Line Biotech stock overvalued right now?
Q-Line Biotech (NSE:QLINE) has a current Ending Cash Position of ₹126 Mil. The current Ending Cash Position is ₹126 Mil. Q-Line Biotech's overall GF Score™ is 14/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For Q-Line Biotech (NSE:QLINE), the current Ending Cash Position is ₹126 Mil as of Mar. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Q-Line Biotech Business Description

Address Kanpur Road Adjacent Transport Nagar Metro Station, 298-281, Transport Nagar, Lucknow, UP, IND, 226012
Q-Line Biotech Ltd is engaged in the business of developing, manufacturing and marketing of diverse range of reagents (including kits and POC devices) & consumables and manufacturing, importing, distribution/supply of diagnostic equipment for different diagnostic healthcare needs. The company supplies diagnostic equipment and IVD products for different diagnostic healthcare needs directly or through its distributors majorly to diagnostic service providers, hospitals and medical colleges. It is engaged in Manufacturing and Trading into Biochemistry Regnant, Instruments and Consumables. The majority of revenue is derived from the Manufacturing segment.
14GF Score

Get the complete analysis for NSE:QLINE

Ending Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹531.80
Price